Elutia Inc. reported progress in the FDA review of its NXT-41 product and preparations for the NXT-41x submission, targeting clearance by early 2027. The company has launched a new automated manufacturing process aiming for gross margins above 80%, supporting competitive pricing. Engagement with surgeons confirms a significant unmet need in the $1.5 billion U.S. breast reconstructive surgery market, where post-operative infection rates remain high. Elutia also maintains a strong cash position of $36.5 million and is exploring strategic options for other product lines, with a conference call scheduled to discuss Q1 2026 results.
Intel recently sold $20 billion worth of its stock at $95 per share. Since the sale, the stock price has dropped and is now trading below $93. This decline means investors who bought at the offering price are facing immediate losses. The price moveme...
Masayoshi Son holds 67% of SoftBank's U.S. stock portfolio in Intel shares. Despite this large stake, SoftBank did not purchase any additional Intel shares in the last quarter. This suggests a pause or cautious approach in expanding their investment ...
Monad (MON) price surged over 12% after breaking out of a two-month sideways range, driven by a sharp increase in daily DEX volume and network activity. The chain's Total Value Locked (TVL) more than doubled to $2.677 billion, while stablecoin market...
Stellar (XLM) surged 22% this week to $0.191, following XRP's 41% rally. XLM is targeting a medium-term breakout, with key resistance between $0.217 and $0.230. Stellar leads in real-world asset tokenization, with over $3 billion in tokenized assets ...
Solana exchange-traded funds (ETFs) attracted $15 million in inflows during their largest session in three weeks. This surge indicates renewed investor interest in Solana-based assets, potentially driven by positive market sentiment or developments r...
